Teva Pharmaceuticals Issues Statement on a Statement by U.S. Department of Health and Human Services Secretary Kathleen Se

NORTH WALES, Pa.--(BUSINESS WIRE)-- We commend the FDA for making the recommendation to approve providing women with increased over-the-counter (OTC) access to Plan B One-Step® and we are disappointed that at this late date, the Department of Health and Human Services has come to a different conclusion. We have not yet received the Complete Response Letter at this time. We will review the letter when we receive it and then determine our next steps.



CONTACT:

Media:
Teva USA
Denise Bradley, 215-591-8974
[email protected]

KEYWORDS:   United States  North America  Pennsylvania

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Other Health  FDA  General Health

MEDIA:

Suggested Articles

German viral vector CDMO Vibalogics has hired Lonza veteran Tom Hochuli as global CEO to help lead its U.S. expansion efforts.

Merck’s Keytruda already boasts an OK in some esophageal cancer patients, but it’s looking to widen its reach in the tough-to-treat disease.

GI cancers are stubborn, as plenty of oncology drugmakers know. But BMS' Opdivo has broken through with two potentially practice-changing trials.